Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

Company Overview

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $2.47 to $2.60
• 50-Day Range: $1.84 to $2.71
• 52-Week Range: $0.90 to $2.96
• Volume: 4,677 shs
• Average Volume: 102,366 shs
• Market Capitalization: $92.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Armata Pharmaceuticals Stock Analysis - MarketRank™

Armata Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Armata Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($1.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Armata Pharmaceuticals is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Armata Pharmaceuticals is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.47% of the float of Armata Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Armata Pharmaceuticals has recently decreased by 24.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Armata Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Armata Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.47% of the float of Armata Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Armata Pharmaceuticals has recently decreased by 24.85%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.57% of the stock of Armata Pharmaceuticals is held by institutions.

ARMP Stock Analysis - Frequently Asked Questions

How have ARMP shares performed this year?

Armata Pharmaceuticals' stock was trading at $2.00 at the start of the year. Since then, ARMP stock has increased by 27.3% and is now trading at $2.5450.

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.02. The company had revenue of $1.23 million for the quarter, compared to the consensus estimate of $0.90 million.

Who are Armata Pharmaceuticals' major shareholders?

Armata Pharmaceuticals' top institutional investors include GSB Wealth Management LLC (0.08%).
View institutional ownership trends.

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Vaxart (VXRT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN).

Company Calendar

• Last Earnings: 11/14/2023
• Today: 8/28/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:ARMP
• CIK: 921114
• Web: www.armatapharma.com
• Phone: (310) 655-2928
• Fax: 310-665-2963
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Armata Pharmaceuticals: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +253.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.92 million
• Net Margins: -374.30%
• Pretax Margin: -374.30%
• Return on Equity: N/A
• Return on Assets: -24.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $5.17 million
• Price / Sales: 17.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.92) per share
• Price / Book: -1.33

Miscellaneous

• Outstanding Shares: 36,230,000
• Free Float: 5,616,000
• Market Cap: $92.21 million
• Optionable: Not Optionable
• Beta: 0.99